Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Invested Capital: 2010-2025

Historic Invested Capital for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $22.0 million.

  • Lineage Cell Therapeutics' Invested Capital fell 65.98% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 65.98%. This contributed to the annual value of $78.4 million for FY2024, which is 23.59% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Invested Capital stood at $22.0 million for Q3 2025, which was down 54.45% from $48.4 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Invested Capital peaked at $124.7 million during Q2 2021, and registered a low of $22.0 million during Q3 2025.
  • In the last 3 years, Lineage Cell Therapeutics' Invested Capital had a median value of $66.9 million in 2024 and averaged $63.8 million.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 32.23% in 2021, then crashed by 65.98% in 2025.
  • Lineage Cell Therapeutics' Invested Capital (Quarterly) stood at $92.3 million in 2021, then decreased by 20.38% to $73.5 million in 2022, then fell by 13.66% to $63.4 million in 2023, then grew by 23.59% to $78.4 million in 2024, then slumped by 65.98% to $22.0 million in 2025.
  • Its last three reported values are $22.0 million in Q3 2025, $48.4 million for Q2 2025, and $79.0 million during Q1 2025.